Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Published in Circulation, Tresukosol et al evaluated VesCell™ in a phase I clinical trial of 24 patients suffering from chronic stable angina. The results showed statistically significant improvements in several important measures of heart function and quality of life. Patients walked 24% farther during the six-minute walk test (p < 0.001), increased their exercise capacity at three months (p < 0.004) , experienced a 45% reduction in the area of the heart receiving inadequate blood flow as measured by SPECT imaging (p < 0.004), and saw their angina severity cut approximately in half on the Canadian Cardiovascular Society (CCS) Angina Scale (p < 0.001). In medical research, p-values <0.05 are generally considered statistically significant. The p-values reported in Hemostemix' study were substantially lower, providing strong statistical evidence that the observed improvements were unlikely to have occurred by chance.
VesCell™ Vascular Dementia Case Study: Before treatment, Mrs. L. had experienced a loss of executive function, short and long-term memory, judgment, and the ability to independently perform activities of daily living. Seven years post treatment, in a telephone call with four physicians and Thomas Smeenk, Mrs. L reported that within six months of her VesCell™ treatment, she regained her ability to live independently. During the 12 minute call, Mrs. L clearly recalled her "wonderful" treatment experience, her career, her child bearing years and family, and her active social calendar with the ease of a cognitively healthy individual. At the conclusion of the discussion, Mrs L invited the treating physician to lunch, to "…thank him again for giving me my life back." While an individual patient experience does not establish clinical efficacy, Mrs L's case illustrates the functional improvements that Hemostemix is evaluating in its commercial vascular dementia clinical trial.
Vascular Dementia debilitates an estimated 50-55 million people worldwide, representing one of the largest unmet needs in neurology. There are currently no approved therapies designed to regenerate the damaged microvasculature responsible for cognitive decline.